Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Joshua White

Emergency Medical Services Lansing, MI Medical Doctor

NPI 1083729933 CMS profile 48829

401 W Greenlawn, Lansing, MI 48910

Open in the dashboard

General payments

$26,247

16 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joshua White of Lansing, MI is reported in the CMS Open Payments database as having received $26,247 across 16 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Emergency Medical Services profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $125 1
2023 General $10,847 6
2022 General $15,275 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua White
  • Emergency Medical Services median
  • Middle half of Emergency Medical Services
  • National median

In program year 2025, general payments to Joshua White were reported at $125. Among 443 Emergency Medical Services profiles paid that year, the median was $72 and the middle half received between $25 and $169.

Show as a table
Year Joshua White Emergency Medical Services median Middle half National median
2019 $0 $62 $20–$162 $163
2020 $0 $37 $17–$119 $114
2021 $0 $58 $20–$133 $132
2022 $15,275 $61 $21–$156 $149
2023 $10,847 $58 $21–$173 $160
2024 $0 $62 $24–$161 $164
2025 $125 $72 $25–$169 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $26,108 14 payments
  2. ITI, Inc. $138 2 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Consulting Fee $25,633 13 payments
  2. Education $475 1 payment
  3. Food and Beverage $138 2 payments
Products named General payments · program years 2022–2025
  1. CAPLYTA Psychiatry $125 1 payment
  2. CAPLYTA Psychiatry $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

191

Median for Emergency Medicine: 88

Drug cost

$14,637

Median for Emergency Medicine: $590

Branded share of claims

37.2%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 24 $7,709
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 27 $6,109
Doxycycline Hyclate Generic 33 $213
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 20 $197
Clindamycin Hcl Generic 14 $148
Cephalexin Generic 23 $110
Ciprofloxacin Hcl Generic 24 $101
Prednisone Generic 26 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$6,383

Medicare's payments for the services billed

Medicare patients

42

Average age 82

Services billed

96

21 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Heart failure 50%
Atrial fibrillation 50%
Ischemic heart disease 48%
Diabetes 43%
Chronic kidney disease 43%
COPD 43%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

16 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medical Services in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record